Amarantus BioScience Holdings, Inc. (AMBS)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Amarantus BioScience Holdings, Inc. (AMBS) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 52/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Amarantus BioScience Holdings, Inc. (AMBS) Gesundheitswesen & Pipeline-Uebersicht
Amarantus BioScience Holdings, Inc. is a biotechnology firm developing diagnostics and therapeutics primarily for neurological disorders, including Alzheimer's and Parkinson's disease. Operating within the competitive healthcare sector, the company focuses on innovative solutions like the LymPro test and Eltoprazine, targeting unmet needs in neurodegenerative diseases.
Investmentthese
Amarantus BioScience Holdings, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on neurodegenerative diseases, an area with significant unmet medical needs, offers substantial market potential. Key value drivers include the successful clinical development and commercialization of LymPro for Alzheimer's disease and Eltoprazine for Parkinson's disease. The company's gross margin is 100.0%. Upcoming clinical trial results for Eltoprazine and progress in the development of ESS for severe burns could serve as positive catalysts. However, the company's negative profit margin of -4995.2% and OTC market listing highlight significant financial and operational risks. The beta of -12.34 suggests high volatility.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00, reflecting the company's current lack of profitability.
- Gross margin of 100.0%, suggesting strong potential profitability if products are successfully commercialized.
- Profit margin of -4995.2%, highlighting the company's significant losses and need for additional funding.
- Beta of -12.34, indicating high volatility and a negative correlation with the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary diagnostic platforms (LymPro, MSPrecise).
- Therapeutic pipeline targeting unmet needs in neurology (Eltoprazine).
- Cooperative research agreements with reputable institutions.
- Focus on innovative solutions for neurodegenerative diseases.
Schwaechen
- Limited financial resources and negative profit margins.
- Dependence on successful clinical trial outcomes.
- OTC market listing indicating higher risk.
- Small market capitalization and limited trading volume.
Katalysatoren
- Upcoming: Clinical trial results for Eltoprazine in Parkinson's disease Levadopa-Induced Dyskinesia.
- Upcoming: Progress in the development of Engineered Skin Substitute (ESS) for severe burns.
- Ongoing: Potential for strategic partnerships and licensing agreements.
- Ongoing: Advancements in the development of LymPro for Alzheimer's disease.
- Ongoing: Research and development progress on NuroPro, BC-SeraPro, and PhenoGuard platforms.
Risiken
- Potential: Unsuccessful clinical trial outcomes for key product candidates.
- Potential: Regulatory hurdles and delays in obtaining approvals for diagnostic and therapeutic products.
- Ongoing: Limited financial resources and dependence on additional funding.
- Ongoing: Competition from larger pharmaceutical and biotechnology companies.
- Ongoing: OTC market listing indicating higher risk and lower liquidity.
Wachstumschancen
- Advancement of LymPro for Alzheimer's Disease: The Alzheimer's disease diagnostics market is projected to reach billions of dollars by 2028. Successful clinical validation and commercialization of LymPro could provide Amarantus with a significant revenue stream. The timeline for commercialization depends on clinical trial results and regulatory approvals, potentially within the next 3-5 years.
- Development of Eltoprazine for Parkinson's Disease: The market for Parkinson's disease treatments is substantial and growing. Positive clinical trial results for Eltoprazine could lead to regulatory approval and market entry, offering a significant growth opportunity for Amarantus. This could materialize within the next 4-6 years, contingent on trial outcomes and regulatory processes.
- Expansion of Engineered Skin Substitute (ESS) for Severe Burns: The market for advanced wound care products, including skin substitutes, is expanding. Successful clinical trials and commercialization of ESS could provide Amarantus with a valuable product in this market. Mid-stage clinical development suggests potential market entry within the next 3-5 years.
- Leveraging NuroPro, BC-SeraPro, and PhenoGuard Platforms: These diagnostic platforms offer potential for developing new diagnostic tests for neurodegenerative diseases and cancer. Successful development and commercialization could generate additional revenue streams for Amarantus. The timeline for these platforms is dependent on research and development progress, potentially yielding results within the next 2-4 years.
- Strategic Partnerships and Collaborations: Amarantus's cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University provides access to valuable resources and expertise. Forming additional strategic partnerships could accelerate the development and commercialization of its products. These partnerships could materialize at any time, providing ongoing growth opportunities.
Chancen
- Expanding market for Alzheimer's and Parkinson's disease diagnostics and therapeutics.
- Potential for strategic partnerships and licensing agreements.
- Advancements in regenerative medicine and cell therapy.
- Government funding and research grants for neurodegenerative disease research.
Risiken
- Regulatory hurdles and lengthy approval processes.
- Competition from larger pharmaceutical and biotechnology companies.
- Patent expiration and generic competition.
- Unsuccessful clinical trial outcomes.
Wettbewerbsvorteile
- Proprietary diagnostic and therapeutic technologies.
- Intellectual property protection through patents and trade secrets.
- Cooperative research and development agreements with leading research institutions.
- Focus on niche markets with unmet medical needs.
Ueber AMBS
Founded in 2008 and headquartered in New York City, Amarantus BioScience Holdings, Inc. is a biopharmaceutical company dedicated to the development of diagnostic and therapeutic solutions for a range of medical conditions. The company's initial focus was on regenerative medicine before expanding into neurology, psychiatry, and ophthalmology. Its diagnostic pipeline features the LymPro test, a blood test designed for the early detection of Alzheimer's disease, and MSPrecise, a DNA sequencing assay aimed at identifying patients with multiple sclerosis. On the therapeutic front, Amarantus is developing Eltoprazine, a small molecule drug intended for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders. Additionally, the company is exploring the potential of mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating various conditions, including retinitis pigmentosa and retinal artery occlusion, in animal models. Amarantus also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company is also developing Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. Formerly known as Amarantus Bioscience, Inc., the company rebranded to Amarantus BioScience Holdings, Inc. in April 2013.
Was das Unternehmen tut
- Develop diagnostic blood tests for Alzheimer's disease (LymPro).
- Develop DNA sequencing assays for identifying patients with multiple sclerosis (MSPrecise).
- Develop small molecule drugs for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia (Eltoprazine).
- Develop neurotrophic factors for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.
- Develop neurodegenerative disease diagnostic platforms with application in Parkinson's disease (NuroPro).
- Develop oncology diagnostic platforms with application in breast cancer (BC-SeraPro).
- Develop platforms for neurrotrophic factor discovery (PhenoGuard).
- Develop Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product for the treatment of life-threatening severe burns.
Geschaeftsmodell
- Develop and commercialize diagnostic tests for neurodegenerative diseases.
- Develop and commercialize therapeutic drugs for neurological and psychiatric disorders.
- Out-license or partner with other companies for the development and commercialization of its products.
- Generate revenue through product sales, licensing agreements, and research grants.
Branchenkontext
Amarantus BioScience Holdings, Inc. operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and significant market potential. The industry is driven by innovation in diagnostics and therapeutics, particularly in areas like neurodegenerative diseases, where there are substantial unmet needs. Amarantus competes with both large pharmaceutical companies and smaller biotech firms, including ACBM, AFFY, BSSP, DECN, and ENDV, focusing on niche markets and innovative technologies to differentiate itself.
Wichtige Kunden
- Patients with Alzheimer's disease, multiple sclerosis, Parkinson's disease, and other neurological disorders.
- Hospitals and clinics that diagnose and treat these conditions.
- Pharmaceutical companies that may license or partner with Amarantus for the development and commercialization of its products.
- Research institutions and government agencies that fund research on neurodegenerative diseases.
Finanzdaten
Chart & Info
Amarantus BioScience Holdings, Inc. (AMBS) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
defenseworld.net · 15. März 2026
-
Contrasting Amarantus Bioscience (OTCMKTS:AMBS) & Progyny (NASDAQ:PGNY)
defenseworld.net · 9. Feb. 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AMBS.
Kursziele
Wall-Street-Kurszielanalyse fuer AMBS.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von AMBS auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: John Wesley Commissiong
CEO
John Wesley Commissiong serves as the Chief Executive Officer of Amarantus BioScience Holdings, Inc. His background includes experience in the biotechnology and pharmaceutical industries. Further details regarding his career history, education, and previous roles are not available from the provided source data.
Erfolgsbilanz: Specific achievements and strategic decisions under John Wesley Commissiong's leadership are not detailed in the provided source data. Therefore, a comprehensive assessment of his track record is not possible.
AMBS OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Amarantus BioScience Holdings, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and less stringent listing standards, resulting in higher risk for investors.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or mismanagement.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility and potential for manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags or material events.
- Consult with a qualified financial advisor before investing.
- Cooperative research agreements with reputable institutions (U.S. Army Institute of Surgical Research and Rutgers University).
- Development of diagnostic and therapeutic products targeting significant unmet medical needs.
- History of operations since 2008.
- Focus on innovative technologies and scientific research.
Was Anleger ueber Amarantus BioScience Holdings, Inc. (AMBS) wissen wollen
What are the key factors to evaluate for AMBS?
Amarantus BioScience Holdings, Inc. (AMBS) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary diagnostic platforms (LymPro, MSPrecise).. Primary risk to monitor: Potential: Unsuccessful clinical trial outcomes for key product candidates.. This is not financial advice.
How frequently does AMBS data refresh on this page?
AMBS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AMBS's recent stock price performance?
Recent price movement in Amarantus BioScience Holdings, Inc. (AMBS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary diagnostic platforms (LymPro, MSPrecise).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AMBS overvalued or undervalued right now?
Determining whether Amarantus BioScience Holdings, Inc. (AMBS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AMBS?
Before investing in Amarantus BioScience Holdings, Inc. (AMBS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AMBS to a portfolio?
Potential reasons to consider Amarantus BioScience Holdings, Inc. (AMBS) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary diagnostic platforms (LymPro, MSPrecise).. Additionally: Therapeutic pipeline targeting unmet needs in neurology (Eltoprazine).. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of AMBS?
Yes, most major brokerages offer fractional shares of Amarantus BioScience Holdings, Inc. (AMBS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AMBS's earnings and financial reports?
Amarantus BioScience Holdings, Inc. (AMBS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AMBS earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited financial data available.
- OTC market listing indicates higher risk.
- AI analysis pending.